Urology Disease Articles & Analysis
6 news found
One patient who could not be completely resected during their pre-instillation ureteroscopy demonstrated partial response to Jelmyto that enabled residual disease to be resected with durable response at five months after last ablation. ...
In patients who recur, it is estimated that 68 percent will experience two or more recurrence episodes throughout the course of their disease, a considerably high and frequent rate in contrast to other non-metastatic cancers. ...
(Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided an overview of the Company’s recent developments. ...
(Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that the Company has entered into a strategic funding agreement with RTW Investments, LP and its affiliated entities (“RTW”). ...
Lite-Med collaborated with UAA and shared the case study results of LM-9200ELMA and LM-IASO at conference of urological disease treatment using extracoporeal shock wave lithotripsy (ESWL) at Royal Phnom Penh Hospital, Cambodia, January 2019. ...
As studies have previously indicated that volatile organic compounds specific to bladder cancer may exist in urine headspace, scientists have decided to research this further by analysing urine samples from two goups; patients diagnosed with bladder cancer or a non-cancerous urological disease or infection, and from healthy ...